Comparative Pharmacology
Head-to-head clinical analysis: BACLOFEN versus GABLOFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACLOFEN versus GABLOFEN.
BACLOFEN vs GABLOFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
None Documented
None Documented
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Clinical Note
moderateBaclofen + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Baclofen is combined with Fluticasone propionate."
Clinical Note
moderateBaclofen + Clemastine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Clemastine."
Clinical Note
moderateBaclofen + Venlafaxine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Venlafaxine."
Clinical Note
moderateBaclofen + Nefazodone
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Baclofen is combined with Nefazodone."